Dec 10 2008
Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I) today announced that it has received the prestigious Frost & Sullivan 2009 Enabling Technology Award in the PET (positron emission tomography) and PET/CT (computed tomography) medical imaging markets. Zecotek received this Award in recognition of the Company's research and development and clinical validation achievements for its next-generation scintillation crystals and solid-state photo detector technology.
"We are extremely impressed with Zecotek's best practices in strategic alliances and technology development of medical imaging products," said Travis Chong, Industry Analyst, Medical Devices, Healthcare of Frost and Sullivan. "We expect their advanced scintillation crystals and solid-state photo detectors to act as a springboard to delivering next-generation oncology and neurology imaging equipment, such as the first-ever combined PET/MRI scanner, accelerating the delivery of truly personalized medicine to the general public."
"Being recognized for our leading edge technologies, which allow for improved and less expensive oncology and neurology diagnostics, is second only to delivering better health care to more people," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek. "At Zecotek we are driven by the needs of our community and our reward is seeing our new technologies being put into action and helping those around us."
Zecotek Photonics distinguished itself from its competitors through its best practices in strategic alliances and technology developments for its medical imaging products. The Company is favorably positioned as a global competitor due to:
1) Integrating a portfolio of technologies to create higher resolution and compact medical imaging devices;
2) Receiving patents for its LFS scintillation crystals in multiple countries including: USA, China, Europe, Russia, Japan and Canada;
3) Achieving a series of pending and granted patents for its novel MAPD solid-state photo detector;
4) Filing a number of patent applications for its important, novel Depth of Interaction design considerations.
"What truly stands out about Zecotek is that development, commercialization, and IP protection of its enabling technologies have all been accomplished since the company's inception only five years ago in 2003," concluded Mr. Chong.
Zecotek Photonics continues to achieve significant steps in the evolution of its industry-changing technologies. The Company has secured strategic partnerships with a number of pioneers within and outside the medical imaging arena. The Company's ability to secure strategic partnerships and joint ventures with Northrop Grumman, Fujikura Ltd. and Frost & Sullivan award winner the Malaysian Institute for Microelectronics Systems (MIMOS), speak volumes of the implementation of best practices in founding a truly global presence for its enabling technologies.
The recent agreements with T.E.M. Incorporated of Japan and Toyo Ram, an Israel distributor, have established secure channels to market through strategic alliances with top-tier industry participants around the globe, ensuring its ability to meet high volume demands and deliver cost-effective products. The Company also continues to validate and create new clinical value for its technologies, especially in the oncology, neurology, imaging arena leading to enhanced patient management and clinical outcomes.